Follow-The-Filings

Security

Avalo Therapeutics Inc. · COM NEW

Equity holders as of 2026 Q1 (each manager’s latest book)

9 owners 1 new max 0.1% (Farallon Capital Manageme...)

owners 9
max % 0.1%
tracked value $75M
qoq N 1 A 5 R 2

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Farallon Capital Management LLC 2026 Q1 0.1% New 0.1% 916,000 $14M hist
Steve Cohen - Point72 Asset Management, L.P. 2026 Q1 0.0% Add 0.00 pp 916,142 $14M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Add 0.00 pp 835,484 $12M hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% Add 0.00 pp 731,586 $11M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 804,084 $15M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Reduce 0.00 pp 193,735 $3M hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit 0.00 pp 148,237 $3M hist
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% Reduce -0.01 pp 129,136 $2M hist
Renaissance Technologies LLC 2026 Q1 0.0% Add 0.00 pp 120,114 $2M hist

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.92M $441,000 $59,000
Gross profit * $640,000
Gross margin * 33.3%
Net income -$31.54M -$35.13M -$78.26M
Net margin * -1639.5% -7965.8% -132642.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $8.4M $138.89M $105.29M
Total non-current assets * $12.6M $11.84M $11.17M
Total assets $20.99M $150.73M $116.46M
Total current liabilities $4.62M $6.96M $12.94M
Total non-current liabilities * $9.07M $10.74M $20.47M
Total equity $7.3M $133.03M $83.05M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$30.68M -$49.06M -$51.46M
Cash from investing -$133,000 $356,000 -$81.72M
Cash from financing $25.04M $175.85M $14.59M
Net change in cash -$5.77M $127.15M -$118.59M

ownership over time

filing count by report period · click a bar for that quarter’s holders